Novo Nordisk A/S (NYSE:NVO) Receives $427.00 Average PT from Brokerages

Novo Nordisk A/S (NYSE:NVOGet Rating) has been assigned an average recommendation of “Hold” from the seventeen research firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $532.75.

A number of equities analysts recently weighed in on NVO shares. Stifel Nicolaus began coverage on Novo Nordisk A/S in a report on Monday, February 28th. They issued a “buy” rating for the company. Citigroup raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, March 2nd. Berenberg Bank upped their price target on Novo Nordisk A/S from 530.00 to 585.00 and gave the company a “hold” rating in a research report on Tuesday, March 1st. JPMorgan Chase & Co. lowered Novo Nordisk A/S from an “overweight” rating to a “neutral” rating in a research report on Monday, December 20th. Finally, Liberum Capital lowered Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Tuesday, January 25th.

Several hedge funds and other institutional investors have recently made changes to their positions in NVO. Ahrens Investment Partners LLC acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at $25,000. Bell Investment Advisors Inc purchased a new position in shares of Novo Nordisk A/S during the third quarter worth about $28,000. Cornerstone Advisory LLC purchased a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $28,000. Fortis Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the third quarter worth about $29,000. Finally, Clearstead Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 109.3% during the third quarter. Clearstead Advisors LLC now owns 314 shares of the company’s stock worth $30,000 after buying an additional 164 shares during the last quarter. Institutional investors and hedge funds own 10.80% of the company’s stock.

NYSE NVO opened at $118.20 on Thursday. The company has a quick ratio of 0.66, a current ratio of 0.86 and a debt-to-equity ratio of 0.18. Novo Nordisk A/S has a 52 week low of $71.18 and a 52 week high of $122.16. The stock’s 50-day moving average price is $107.47 and its 200-day moving average price is $106.39. The company has a market capitalization of $278.34 billion, a P/E ratio of 35.82, a price-to-earnings-growth ratio of 2.77 and a beta of 0.51.

Novo Nordisk A/S (NYSE:NVOGet Rating) last issued its quarterly earnings results on Wednesday, February 2nd. The company reported $0.73 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.71 by $0.02. The firm had revenue of $5.89 billion during the quarter, compared to analyst estimates of $5.63 billion. Novo Nordisk A/S had a return on equity of 72.70% and a net margin of 34.00%. During the same period last year, the company earned $0.64 EPS. Research analysts anticipate that Novo Nordisk A/S will post 3.31 EPS for the current year.

The business also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 5th. Stockholders of record on Monday, March 28th were paid a $0.741 dividend. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.56. This represents a dividend yield of 1.1%. The ex-dividend date of this dividend was Friday, March 25th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 44.85%.

About Novo Nordisk A/S (Get Rating)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

Read More

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with's FREE daily email newsletter.